Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Caris Life Sciences Selects Illumina’s MiSeq® System

Published: Friday, November 09, 2012
Last Updated: Friday, November 09, 2012
Bookmark and Share
Collaboration enhances breadth and depth of therapeutic information to help oncologists better personalize cancer treatment.

Illumina, Inc. has announced that Caris Life Sciences has selected its MiSeq sequencing system to support Caris' evidence-based molecular profiling service.

The MiSeq system will be deployed to enable rapid, simultaneous analysis of multiple genes from formalin-fixed, paraffin-embedded (FFPE) tumor tissues using Illumina's amplicon-based assay.

Caris Life Sciences' molecular profiling service offers comprehensive tumor biomarker analyses coupled with an extensive clinical literature review, which matches potential therapies to patient-specific biomarker information.

Using a wide array of the most clinically relevant technologies available, this service continually evolves with the emerging science to help oncologists personalize care for cancer patients.

The addition of next-generation sequencing to Caris' molecular profiling service represents the next step in the natural evolution of this cutting-edge offering.

"We are pleased to be the selected sequencing platform for Caris Life Sciences, an unmatched leader in tumor profiling, whose molecular profiling service has been ordered for more than 40,000 patients to date," said Matt Posard, Senior Vice President and General Manager of Illumina's Translational and Consumer Genomics business.

Posard continued, "This collaboration is an excellent example of applying next-generation sequencing with the goal of improving patient outcomes."

Caris Life Sciences is one of the few entities to offer next-generation sequencing commercially in their CLIA-accredited laboratory, and will replace its current sequencing technology with Illumina's MiSeq system.

The addition of next-generation sequencing via the MiSeq complements the variety of highly integrated technology platforms already employed by Caris, including immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and polymerase chain reaction (PCR).

Caris' molecular profiling service uses these cutting-edge technologies to comprehensively interrogate the entire cancer biological process - including DNA, RNA, and protein analysis.

"Caris leverages the most clinically relevant technologies and biomarkers to help physicians individualize care. When we choose to add a new technology to our portfolio, we are committed to selecting a best-in-class platform and partner, as evidenced by our selection of Illumina," said Tom Spalding, Senior Vice President, Group Head Oncology and Chief Marketing Officer at Caris Life Sciences.

Spalding continued, "After a thorough evaluation of top NGS platforms, Illumina's data quality, simple workflow, and commitment to a collaborative approach were key to our decision to work with them."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Illumina Forms New Company
GRAIL to enable early cancer detection via blood-based screening.
Tuesday, January 12, 2016
Verinata Health's verifi® Prenatal Test Available through the California Prenatal Screening Program
verifi® prenatal test will be available to pregnant women in California.
Tuesday, November 05, 2013
Illumina Acquires Advanced Liquid Logic
Acquisition a key component in the development of complete sample-to-answer solutions for next-generation sequencing.
Wednesday, July 24, 2013
BGI Purchases 128 Illumina HiSeq™ 2000 Sequencing Systems
Acquisition puts Beijing Genomics Institute on path to become world's largest sequencing facility.
Thursday, January 14, 2010
Expression Analysis Purchases its First Illumina Genome Analyzer
Illumina's Genome Analyzer sequencing technology will support EA's new plant and animal genomic services.
Friday, January 09, 2009
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!